PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28164237-2	2017	Germline variants in succinate dehydrogenase genes (SDHx) co-occurring with PTEN germline mutations confer a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS.	sdhx	52-56	phosphatase and tensin homolog	Homo sapiens	76-80	
28164237-2	2017	Germline variants in succinate dehydrogenase genes (SDHx) co-occurring with PTEN germline mutations confer a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS.	sdhx	264-268	phosphatase and tensin homolog	Homo sapiens	76-80	
22261759-6	2012	CONCLUSION: Our data suggest that mutations in PTEN, SDHB, and SDHD reduce catalytic activity of succinate dehydrogenase, resulting in succinate accumulation, and identify a common biochemical alteration in these two patient populations (PTEN and SDHx mutation positive individuals).	sdhx	247-251	phosphatase and tensin homolog	Homo sapiens	47-51	
22261759-6	2012	CONCLUSION: Our data suggest that mutations in PTEN, SDHB, and SDHD reduce catalytic activity of succinate dehydrogenase, resulting in succinate accumulation, and identify a common biochemical alteration in these two patient populations (PTEN and SDHx mutation positive individuals).	sdhx	247-251	phosphatase and tensin homolog	Homo sapiens	238-242	
21979946-5	2012	We then found that SDHx variants also occur in 6% (26/444) of PTEN mutation-positive (PTEN(mut+)) CS/CSL individuals (PTEN(mut+)/SDH(var+)).	sdhx	19-23	phosphatase and tensin homolog	Homo sapiens	62-66	
21979946-5	2012	We then found that SDHx variants also occur in 6% (26/444) of PTEN mutation-positive (PTEN(mut+)) CS/CSL individuals (PTEN(mut+)/SDH(var+)).	sdhx	19-23	phosphatase and tensin homolog	Homo sapiens	86-90	
21979946-5	2012	We then found that SDHx variants also occur in 6% (26/444) of PTEN mutation-positive (PTEN(mut+)) CS/CSL individuals (PTEN(mut+)/SDH(var+)).	sdhx	19-23	phosphatase and tensin homolog	Homo sapiens	86-90	
21956414-6	2011	SDHx mutation analysis occurred in those without PTEN mutations/variations and elevated manganese superoxide dismutase (MnSOD) levels.	sdhx	0-4	phosphatase and tensin homolog	Homo sapiens	49-53	
21956414-10	2011	Standardized incidence rates for thyroid cancer were 72 [95% confidence interval (CI), 51-99; P < 0.001] for pathogenic PTEN mutations, 63 (95% CI, 42-92; P < 0.001) for SDHx variants, and 45 (95% CI, 26-73; P < 0.001) for KLLN epimutations.	sdhx	176-180	phosphatase and tensin homolog	Homo sapiens	123-127